TK2 and myopathy: Treatment-related marked improvements of mtDNA levels and biochemical defects in muscle, which is the most affected tissue in TK2 mutant patients, suggest that dCMP/dTMP might be more efficacious in patients with myopathy due to TK2 deficiency than in Tk2−/− mice with severe CNS involvement.